NCT05702229 2026-03-18
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 2 Recruiting
AstraZeneca
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
AstraZeneca
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Hoffmann-La Roche